Trust in Calyx EDC based on decade-long relationship drives contract extension decision
Nottingham, England and Morrisville, NC – 2022 年 2 月 14 日 – Calyx, the eClinical and Regulatory solutions, and service provider relied on for solving complex data challenges in clinical research, announced today that a Top 20 specialty pharmaceutical company will continue to rely on Calyx’s electronic data capture (EDC) system for a series of upcoming, early phase studies.
The Top 20 specialty pharmaceutical company is furthering its commitment to the relationship it has formed with Calyx and extending its use of the EDC system in multiple additional studies scheduled to begin this year. The company ‒ which has relied on Calyx EDC for over a decade ‒ will use the proven, robust system to capture important clinical trial data in early phase studies of new compounds being developed for diabetes, obesity, and NASH.
“We are so proud of the trust this Top 20 specialty pharmaceutical company places in Calyx EDC and we are delighted to continue supporting their efforts to bring advanced treatment options to the many people living with metabolic disorders and other diseases around the world,” said Juan Munoz-Pujol, Vice President, IRT and EDC at Calyx.
点击这里查看更多关于凯理斯 EDC的资讯。
关于凯理斯
凯理斯是一家全球顶尖的医学影像及临床信息化管理供应商，提供包括独立中心影像评估(IRC)、随机化和药品供应管理系统及服务(IRT)、临床试验管理系统(CTMS) 、临床试验电子数据采集系统(EDC)、eCTD递交及临床法规信息系统(RIM)等全面解决方案。 凯理斯服务申办方和临床研究组织 (CRO)已经近三十年，支持多达 60,000 项试验，成功帮助申办方通过了 650 个新药审批，惠及1,800 万名患者。经过近10年在中国新药研发行业的深耕，凯理斯中国团队已逾百人；通过全面深入的本土化，目前已服务近120家本土企业，同时和国内近10家顶尖药企及创新药公司达成企业级长期战略合作凭借在临床开发方面的深厚专业知识以及在支持试验申办方和临床研究组织方面逾 25 年的经验，凯理斯利用其智慧和经验来解决复杂问题、提供快速见解并每天都将新药推向市场。
Take your trials further with intelligent insights at Calyx.ai or at LinkedIn, Twitter, or Facebook.
联系人：
Christine Tobin | christine.tobin@calyx.ai | +1 412-628-8598
